Skip to content

Human Psychopharmacology: Clinical and Experimental

ISSN 0885-6222, 1099-1077

69 papers in the library · 3,797 citations · publishing 1988-2026

Papers

Sort Most recent Most cited

Novel psychoactive substances (NPS) use in severe mental illness (SMI) patients: Potential changes in the phenomenology of psychiatric diseases

Human Psychopharmacology: Clinical and Experimental May 1, 2017 Giuseppe Bersani, Elisabeth Prevete 15 citations

OBJECTIVE: Literature is quite poor about the clinical effects of novel psychoactive substances (NPS) and the long-term consequences of NPS use in psychiatric patients. Consequently, it is of the greatest interest to examine which effects NPS can exert in patients with previous severe mental illness (SMI), such as psychotic patients. The aim of this work was a comprehensive review about NPS use...

DOI: 10.1002/hup.2591 (opens in new tab) Mental illness Phenomenology philosophy Mental health

Updating of working memory in ecstasy polydrug users: Findings from fNIRS.

Human Psychopharmacology: Clinical and Experimental May 2017 Catharine Montgomery, John E. Fisk, Carl A Roberts

Cognitive deficits are now well documented in ecstasy (MDMA) users with type and relative demand of task emerging as important factors. The updating component of executive processes appears to be particularly affected. The study reported here used functional near infrared spectroscopy imaging to investigate changes in cortical haemodynamics during memory updating. Twenty ecstasy users and 20...

Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.

Human Psychopharmacology: Clinical and Experimental September 1, 2016 José Carlos Bouso, Eduardo José Pedrero-Pérez, Sam Gandy et al. 48 citations

In the present study we explored the psychometric properties of three widely used questionnaires to assess the subjective effects of hallucinogens: the Hallucinogen Rating Scale (HRS), the Mystical Experience Questionnaire (MEQ), and the Addiction Research Center Inventory (ARCI). These three questionnaires were administered to a sample of 158 subjects (100 men) after taking ayahuasca, a...

Methoxetamine‐related deaths in the UK: an overview

Human Psychopharmacology: Clinical and Experimental July 1, 2015 Stefania Chiappini, Hugh Claridge, John Corkery et al. 45 citations

OBJECTIVE: The goal of this study is to provide an update on the data given on methoxetamine (MXE)-related fatalities that occurred in 2011-2013, presented at the Second International Conference on Novel Psychoactive Substances. METHODS: Fatalities involving MXE were extracted from the database of the National Programme on Substance Abuse Deaths, which receives information on drug-related...

Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance‐related psychotic symptoms

Human Psychopharmacology: Clinical and Experimental July 1, 2015 Giuseppe Valeriani, Ornella Corazza, Francesco Saverio Bersani et al. 41 citations

OBJECTIVE: The pharmacological self-management of novel psychoactive substance (NPS)-induced psychopathological consequences represents a fast growing phenomenon. This is facilitated by the frequent sharing of NPS intake experiences online and by the ease of access to a range of psychotropic medications from both the online and street market. Olanzapine is anecdotally reported by Web users to...

DOI: 10.1002/hup.2431 (opens in new tab) Olanzapine Schizophrenia object-oriented programming

Venlafaxine as the ‘baby ecstasy’? Literature overview and analysis of web‐based misusers′ experiences

Human Psychopharmacology: Clinical and Experimental July 1, 2015 Giulia Francesconi, Laura Orsolini, Duccio Papanti et al. 22 citations

INTRODUCTION: Venlafaxine is one of the most frequently prescribed antidepressants worldwide, despite its toxicity risk in overdose. Furthermore, the molecule has been recently identified at the EU-wide level as one of the novel psychoactive substances. This paper aims at investigating the potential of misuse, taking into account both the existing literature and the analysis of the misusers'...

Greater sexual risk-taking in female and male recreational MDMA/ecstasy users compared with alcohol drinkers: a questionnaire study.

Human Psychopharmacology: Clinical and Experimental July 2015 Aimee L May, Andrew C. Parrott

Previous studies have shown increased sexual risk-taking in experienced MDMA/ecstasy users. The main objectives of this study were to compare levels of sexual risk-taking between a young student sample of predominantly heterosexual MDMA users and alcohol-drinker controls and investigate potential gender differences. Recreational drug use and sexual risk questionnaires were completed by 20 MDMA...

The use of ketamine as an antidepressant: a systematic review and meta‐analysis

Human Psychopharmacology: Clinical and Experimental April 7, 2015 Caoimhe M. Coyle, Keith R. Laws 279 citations

Objective The current meta‐analysis examines the effects of ketamine infusion on depressive symptoms over time in major depressive disorder (MDD) and bipolar disorder (BD). Methods Following a systematic review of the literature, data were extracted from 21 studies ( n = 437 receiving ketamine) and analysed at four post‐infusion time points (4 h, 24 h, 7 days and 12–14 days). The moderating...

A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research".

Human Psychopharmacology: Clinical and Experimental March 1, 2014 Rick Doblin, George Greer, Julie Holland et al. 48 citations

Parrott recently published a review of literature on MDMA/ecstasy. This commentary is a response to the content and tenor of his review, which mischaracterizes the literature through misstatement and omission of contrary findings, and fails to address the central controversies in the literature. The review makes several erroneous statements concerning MDMA-assisted psychotherapy, such as...

DOI: 10.1002/hup.2389 (opens in new tab) MDMA Ecstasy Therapeutic potential Controlled therapeutic contexts +6

MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014).

Human Psychopharmacology: Clinical and Experimental March 2014 Andrew C. Parrott

Human Psychopharmacology recently published my review into the increase in empirical knowledge about the human psychobiology of MDMA over the past 25 years (Parrott, 2013a). Deficits have been demonstrated in retrospective memory, prospective memory, higher cognition, complex visual processing, sleep architecture, sleep apnoea, pain, neurohormonal activity, and psychiatric status. Neuroimaging...

Salvia divinorum: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug.

Human Psychopharmacology: Clinical and Experimental September 1, 2013 Jolanta B. Zawilska, Jakub Wojcieszak 34 citations

Salvia divinorum is a sage endemic to a small region of Mexico and has been traditionally used by the Mazatec Indians for divination and spiritual healing. Recently, it has gained increased popularity as a recreational drug, used by adolescents and young adults as an alternative to marijuana and LSD. Salvinorin A, the major active ingredient of the plant, is considered to be the most potent...

“Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report

Human Psychopharmacology: Clinical and Experimental July 1, 2013 Duccio Papanti, Fabrizio Schifano, Giulia Botteon et al. 191 citations

OBJECTIVES: The use of synthetic cannabimimetics (SC; "spice" drugs) is increasing, especially among teenagers and young adults. In parallel with this, the number of studies describing intoxication episodes associated with psychotic symptoms in SC users is growing. We present both a systematic review of the related literature and a case report, which seems to highlight the existence of a...

DOI: 10.1002/hup.2312 (opens in new tab) Psychosis Exacerbation Psychopathology Synthetic cannabinoids +1

Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research

Human Psychopharmacology: Clinical and Experimental July 1, 2013 A. C. Parrott 184 citations

AIMS: This paper aimed to review how scientific knowledge about the human psychobiology of MDMA has developed over time. METHODS: In this paper, the empirical findings from earlier and later studies will be reviewed. RESULTS: When MDMA was a 'novel psychoactive substance', it was not seen as a drug of abuse, as it displayed loss of efficacy. However, recreational users display a unique pattern...

DOI: 10.1002/hup.2318 (opens in new tab) MDMA Ecstasy Behavioral neuroscience Clinical psychology

MDAI (5,6‐methylenedioxy‐2‐aminoindane; 6,7‐dihydro‐5H‐cyclopenta[f][1,3]benzodioxol‐6‐amine; ‘sparkle’; ‘mindy’) toxicity: a brief overview and update

Human Psychopharmacology: Clinical and Experimental July 1, 2013 John Corkery, Simon Elliott, Fabrizio Schifano et al. 52 citations

OBJECTIVES: MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') is a psychoactive substance, sold primarily over the Internet and in 'head' shops as a 'legal high'. Synthesised and used as a research chemical in the 1990s, MDAI has structural similarities to MDMA (3,4-methylenedioxy-N-methylamphetamine) and shares its behavioural...

DOI: 10.1002/hup.2298 (opens in new tab) Amine gas treating Stereochemistry Medicinal chemistry Organic chemistry

Consumption of new psychoactive substances in a Spanish sample of research chemical users.

Human Psychopharmacology: Clinical and Experimental July 1, 2013 Débora González, Mireia Ventura, Fernando Caudevilla et al. 39 citations

To know the pattern of use of new psychoactive substances (NPSs) in a Spanish sample of research chemical (RC) users and to deepen the RC user profile and risk reduction strategies employed. This study is a cross-sectional survey by means of a specific questionnaire. Recruitment was carried out at music festivals, at non-governmental organizations (NGOs), and through announcements on an online...

DOI: 10.1002/hup.2323 (opens in new tab) Full text (opens in new tab) 2c-b Consumption patterns New psychoactive substances Research chemicals +12

Simultaneous polysubstance use among Danish 3,4‐methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases

Human Psychopharmacology: Clinical and Experimental June 14, 2012 Cecilie Löe Licht, M.v. Christoffersen, Mads Okholm et al. 40 citations

Objective To describe patterns of simultaneous polysubstance use (SPU) among Danish 3,4‐methylenedioxymethamphetamine (MDMA) (“Ecstasy”) and hallucinogen users. Methods A cross‐sectional survey of 98 active MDMA and/or hallucinogen users recruited through homepage advertisements, flyers, and word of mouth in Denmark. Lifetime and recent substance use and SPU at last recalled use was described...

DOI: 10.1002/hup.2234 (opens in new tab) Hallucinogen Polysubstance dependence Danish

Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine

Human Psychopharmacology: Clinical and Experimental March 1, 2012 Ornella Corazza, Fabrizio Schifano, Pierluigi Simonato et al. 157 citations

On the basis of the material available both in the scientific literature and on the web, this paper aims to provide a pharmacological, chemical and behavioural overview of the novel compound methoxetamine. This is a dissociative drug related to ketamine, with a much longer duration of action and intensity of effects. A critical discussion of the availability of information on the web of...

DOI: 10.1002/hup.1242 (opens in new tab) Phenomenon The internet Scientific literature Recreation +8

Cannabis‐related deficits in real‐world memory

Human Psychopharmacology: Clinical and Experimental March 1, 2012 Catharine Montgomery, Alexandra L. Seddon, John E. Fisk et al. 56 citations

BACKGROUND: Research shows that cannabis users exhibit deficits in prospective memory (PM) and executive function, which persist beyond acute intoxication. However, many studies rely on self-reports of memory failures or use laboratory-based measures that may not mimic functional deficits in the real world. The present study aimed to assess real-world memory functioning. METHOD: Twenty...

The effects of multitasking on psychological stress reactivity in recreational users of cannabis and MDMA

Human Psychopharmacology: Clinical and Experimental March 1, 2012 Mark Wetherell, Katie Atherton, Jessica Grainger et al. 25 citations

Background Cannabis and 3,4‐methylenedioxymethamphetamine (MDMA) use is associated with psychobiological and neurocognitive deficits. Assessments of the latter typically include tests of memory and everyday cognitive functioning. However, to date, little attention has been paid to effects of drug use on psychological stress reactivity. We report three studies examining the effects of...

DOI: 10.1002/hup.1261 (opens in new tab) MDMA Human multitasking Stressor Neurocognitive +4

Residual effects of ecstasy (3,4‐methylenedioxymethamphetamine) on low level visual processes

Human Psychopharmacology: Clinical and Experimental March 1, 2012 Elizabeth Murray, Raimondo Bruno, John Brown

‘Ecstasy’ (3,4‐methylenedioxymethamphetamine) induces impaired functioning in the serotonergic system, including the occipital lobe. This study employed the ‘tilt aftereffect’ paradigm to operationalise the function of orientation‐selective neurons among ecstasy consumers and controls as a means of investigating the role of reduced serotonin on visual orientation processing. The magnitude of...

5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'.

Human Psychopharmacology: Clinical and Experimental March 2012 Cathal T Gallagher, Sulaf Assi, Jacqueline L. Stair et al.

The fully synthetic 'legal high' 5,6-methylenedioxy-2-aminoindane (MDAI) is an analogue of 3,4-methylenedioxymethamphetamine. Although developed in the 1990s, it was not widely abused until 2010. However, mephedrone was banned in the UK in April 2010, and almost immediately, MDAI was widely advertised as a legal alternative. This paper provides both an overview of the current state of knowledge...

Polydrug use, cannabis, and psychosis‐like symptoms

Human Psychopharmacology: Clinical and Experimental August 1, 2008 Nicholas T. van Dam, Mitch Earleywine, Greg DiGiacomo

AbstractObjectiveTo examine psychosis‐like symptoms in users of legal and illicit drugs.MethodsSchizotypal Personality Questionnaire (SPQ) scores were compared in groups of people with different exposure to cannabis, with the use of other drugs serving as a covariate. Supplemental analyses compared users of legal and illicit drugs with cannabis use as a covariate.ResultsWeekly (n = 111) and...

The neuropsychology of ecstasy (MDMA) use: a quantitative review

Human Psychopharmacology: Clinical and Experimental September 25, 2007 Konstantine K. Zakzanis, Zachariah Campbell, Diana Jovanovski 87 citations

Abstract A growing number of empirical studies have found varying neuropsychological impairments associated with use of 3,4‐methylenedioxymethamphetamine (MDMA) use. We set out to determine to what extent neuropsychological abilities are impaired in MDMA users. To do so, meta‐analytical methods were used to determine the magnitude of neuropsychological impairment in MDMA users across...

Ecstasy (MDMA) and memory function: a meta‐analytic update

Human Psychopharmacology: Clinical and Experimental July 10, 2007 Keith R. Laws, Joy Kokkalis 75 citations

Abstract A meta‐analysis was conducted to examine the impact of recreational ecstasy use on short‐term memory (STM), long‐term memory (LTM), verbal and visual memory. We located 26 studies containing memory data for ecstasy and non‐ecstasy users from which effect sizes could be derived. The analyses provided measures of STM and LTM in 610 and 439 ecstasy users and revealed moderate‐to‐large...